Enzon Pharmaceuticals, Inc. (ENZN)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 47.7 Million USD | 0.24% |
| 2022 | 47.58 Million USD | -0.35% |
| 2021 | 47.75 Million USD | -0.99% |
| 2020 | 48.23 Million USD | 644.55% |
| 2019 | 6.47 Million USD | -58.23% |
| 2018 | 15.51 Million USD | 63.06% |
| 2017 | 9.51 Million USD | -15.61% |
| 2016 | 11.27 Million USD | -50.76% |
| 2015 | 22.89 Million USD | -34.67% |
| 2014 | 35.04 Million USD | 392.07% |
| 2013 | 7.12 Million USD | -96.44% |
| 2012 | 199.78 Million USD | -41.79% |
| 2011 | 343.2 Million USD | -29.79% |
| 2010 | 488.85 Million USD | 46.91% |
| 2009 | 332.74 Million USD | -4.73% |
| 2008 | 349.25 Million USD | -16.92% |
| 2007 | 420.35 Million USD | 4.09% |
| 2006 | 403.83 Million USD | 18.31% |
| 2005 | 341.34 Million USD | -52.91% |
| 2004 | 724.86 Million USD | -0.51% |
| 2003 | 728.56 Million USD | 19.29% |
| 2002 | 610.74 Million USD | 11.11% |
| 2001 | 549.67 Million USD | 322.01% |
| 2000 | 130.25 Million USD | 273.22% |
| 1999 | 34.9 Million USD | 154.74% |
| 1998 | 13.7 Million USD | -14.38% |
| 1997 | 16 Million USD | -27.27% |
| 1996 | 22 Million USD | 14.58% |
| 1995 | 19.2 Million USD | -6.34% |
| 1994 | 20.5 Million USD | -39.53% |
| 1993 | 33.9 Million USD | -13.74% |
| 1992 | 39.3 Million USD | -27.49% |
| 1991 | 54.2 Million USD | 86.25% |
| 1990 | 29.1 Million USD | 117.16% |
| 1989 | 13.4 Million USD | 19.64% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 46.82 Million USD | -1.83% |
| 2024 Q3 | 47.27 Million USD | 0.6% |
| 2024 Q2 | 46.99 Million USD | 0.35% |
| 2023 Q3 | 46.99 Million USD | 0.7% |
| 2023 Q2 | 46.67 Million USD | 0.38% |
| 2023 FY | 47.7 Million USD | 0.24% |
| 2023 Q1 | 46.49 Million USD | -2.3% |
| 2023 Q4 | 47.7 Million USD | 1.5% |
| 2022 Q3 | 47.25 Million USD | 0.07% |
| 2022 Q2 | 47.22 Million USD | -0.52% |
| 2022 Q4 | 47.58 Million USD | 0.7% |
| 2022 Q1 | 47.47 Million USD | -0.59% |
| 2022 FY | 47.58 Million USD | -0.35% |
| 2021 Q4 | 47.75 Million USD | -0.44% |
| 2021 Q1 | 48.29 Million USD | 0.12% |
| 2021 FY | 47.75 Million USD | -0.99% |
| 2021 Q2 | 48.24 Million USD | -0.1% |
| 2021 Q3 | 47.96 Million USD | -0.59% |
| 2020 Q4 | 48.23 Million USD | 728.16% |
| 2020 FY | 48.23 Million USD | 644.55% |
| 2020 Q1 | 6.23 Million USD | -3.72% |
| 2020 Q2 | 6 Million USD | -3.74% |
| 2020 Q3 | 5.82 Million USD | -3.0% |
| 2019 FY | 6.47 Million USD | -58.23% |
| 2019 Q2 | 12.4 Million USD | -1.2% |
| 2019 Q1 | 12.55 Million USD | -19.06% |
| 2019 Q3 | 12.07 Million USD | -2.68% |
| 2019 Q4 | 6.47 Million USD | -46.33% |
| 2018 Q4 | 15.51 Million USD | 77.58% |
| 2018 Q1 | 9.3 Million USD | -2.23% |
| 2018 Q2 | 9.01 Million USD | -3.12% |
| 2018 Q3 | 8.73 Million USD | -3.06% |
| 2018 FY | 15.51 Million USD | 63.06% |
| 2017 FY | 9.51 Million USD | -15.61% |
| 2017 Q4 | 9.51 Million USD | 5.07% |
| 2017 Q3 | 9.05 Million USD | -42.15% |
| 2017 Q2 | 15.64 Million USD | 38.5% |
| 2017 Q1 | 11.29 Million USD | 0.24% |
| 2016 Q2 | 20.79 Million USD | 4.68% |
| 2016 Q1 | 19.86 Million USD | -13.23% |
| 2016 Q3 | 21.74 Million USD | 4.56% |
| 2016 FY | 11.27 Million USD | -50.76% |
| 2016 Q4 | 11.27 Million USD | -48.16% |
| 2015 Q2 | 41.28 Million USD | 9.14% |
| 2015 Q3 | 21.4 Million USD | -48.15% |
| 2015 Q4 | 22.89 Million USD | 6.93% |
| 2015 FY | 22.89 Million USD | -34.67% |
| 2015 Q1 | 37.83 Million USD | 7.96% |
| 2014 FY | 35.04 Million USD | 392.07% |
| 2014 Q3 | 29.32 Million USD | 33.88% |
| 2014 Q2 | 21.9 Million USD | 43.92% |
| 2014 Q1 | 15.21 Million USD | 113.69% |
| 2014 Q4 | 35.04 Million USD | 19.5% |
| 2013 Q2 | 16.64 Million USD | -91.77% |
| 2013 FY | 7.12 Million USD | -96.44% |
| 2013 Q3 | 22.86 Million USD | 37.32% |
| 2013 Q4 | 7.12 Million USD | -68.85% |
| 2013 Q1 | 202.29 Million USD | 1.26% |
| 2012 Q2 | 317.04 Million USD | -5.91% |
| 2012 FY | 199.78 Million USD | -41.79% |
| 2012 Q4 | 199.78 Million USD | -34.38% |
| 2012 Q3 | 304.46 Million USD | -3.97% |
| 2012 Q1 | 336.94 Million USD | -1.82% |
| 2011 Q1 | 444.84 Million USD | -9.0% |
| 2011 FY | 343.2 Million USD | -29.79% |
| 2011 Q2 | 386.69 Million USD | -13.07% |
| 2011 Q4 | 343.2 Million USD | -3.2% |
| 2011 Q3 | 354.53 Million USD | -8.32% |
| 2010 Q2 | 535.79 Million USD | 0.5% |
| 2010 Q4 | 488.85 Million USD | -5.09% |
| 2010 FY | 488.85 Million USD | 46.91% |
| 2010 Q1 | 533.14 Million USD | 60.22% |
| 2010 Q3 | 515.08 Million USD | -3.87% |
| 2009 FY | 332.74 Million USD | -4.73% |
| 2009 Q4 | 332.74 Million USD | -1.46% |
| 2009 Q3 | 337.67 Million USD | 1.99% |
| 2009 Q2 | 331.09 Million USD | -0.24% |
| 2009 Q1 | 331.9 Million USD | -4.97% |
| 2008 Q2 | 364.86 Million USD | 1.95% |
| 2008 FY | 349.25 Million USD | -16.92% |
| 2008 Q4 | 349.25 Million USD | -1.16% |
| 2008 Q3 | 353.35 Million USD | -3.16% |
| 2008 Q1 | 357.88 Million USD | -14.86% |
| 2007 Q4 | 420.35 Million USD | -0.75% |
| 2007 Q3 | 423.51 Million USD | 19.16% |
| 2007 FY | 420.35 Million USD | 4.09% |
| 2007 Q1 | 368.8 Million USD | -8.67% |
| 2007 Q2 | 355.43 Million USD | -3.63% |
| 2006 FY | 403.83 Million USD | 18.31% |
| 2006 Q2 | 516.11 Million USD | 44.65% |
| 2006 Q1 | 356.81 Million USD | 0.0% |
| 2006 Q4 | 403.83 Million USD | 5.06% |
| 2006 Q3 | 384.37 Million USD | -25.53% |
| 2005 Q3 | 645.53 Million USD | -0.82% |
| 2005 FY | 341.34 Million USD | -52.91% |
| 2005 Q2 | 650.86 Million USD | -9.1% |
| 2005 Q1 | 716.02 Million USD | -0.89% |
| 2004 Q2 | 724.86 Million USD | -1.73% |
| 2004 Q3 | 719.18 Million USD | -0.78% |
| 2004 FY | 724.86 Million USD | -0.51% |
| 2004 Q4 | 722.45 Million USD | 0.45% |
| 2004 Q1 | 737.58 Million USD | 0.0% |
| 2003 FY | 728.56 Million USD | 19.29% |
| 2003 Q1 | 623.78 Million USD | -1.6% |
| 2003 Q2 | 728.56 Million USD | 16.8% |
| 2003 Q3 | 726.97 Million USD | -0.22% |
| 2003 Q4 | 737.57 Million USD | 1.46% |
| 2002 FY | 610.74 Million USD | 11.11% |
| 2002 Q1 | 578.72 Million USD | 1.08% |
| 2002 Q3 | 620.37 Million USD | 1.58% |
| 2002 Q2 | 610.74 Million USD | 5.53% |
| 2002 Q4 | 633.91 Million USD | 2.18% |
| 2001 Q2 | 549.67 Million USD | 282.54% |
| 2001 FY | 549.67 Million USD | 322.01% |
| 2001 Q4 | 572.54 Million USD | 2.71% |
| 2001 Q3 | 557.42 Million USD | 1.41% |
| 2001 Q1 | 143.69 Million USD | 6.29% |
| 2000 Q2 | 130.25 Million USD | -4.6% |
| 2000 FY | 130.25 Million USD | 273.22% |
| 2000 Q4 | 135.18 Million USD | -0.45% |
| 2000 Q3 | 135.79 Million USD | 4.25% |
| 2000 Q1 | 136.52 Million USD | 296.88% |
| 1999 Q4 | 34.4 Million USD | -0.58% |
| 1999 Q1 | 34.5 Million USD | 2.68% |
| 1999 Q2 | 34.9 Million USD | 1.16% |
| 1999 FY | 34.9 Million USD | 154.74% |
| 1999 Q3 | 34.6 Million USD | -0.86% |
| 1998 FY | 13.7 Million USD | -14.38% |
| 1998 Q3 | 30 Million USD | 118.98% |
| 1998 Q1 | 15.2 Million USD | -5.0% |
| 1998 Q2 | 13.7 Million USD | -9.87% |
| 1998 Q4 | 33.6 Million USD | 12.0% |
| 1997 Q3 | 16.9 Million USD | 5.63% |
| 1997 Q4 | 16 Million USD | -5.33% |
| 1997 Q1 | 17.6 Million USD | -14.15% |
| 1997 FY | 16 Million USD | -27.27% |
| 1997 Q2 | 16 Million USD | -9.09% |
| 1996 Q4 | 20.5 Million USD | -2.84% |
| 1996 FY | 22 Million USD | 14.58% |
| 1996 Q1 | 23.1 Million USD | 42.59% |
| 1996 Q2 | 22 Million USD | -4.76% |
| 1996 Q3 | 21.1 Million USD | -4.09% |
| 1995 Q2 | 19.2 Million USD | 10.98% |
| 1995 Q4 | 16.2 Million USD | -4.71% |
| 1995 Q3 | 17 Million USD | -11.46% |
| 1995 Q1 | 17.3 Million USD | 8.13% |
| 1995 FY | 19.2 Million USD | -6.34% |
| 1994 Q2 | 20.5 Million USD | -9.69% |
| 1994 Q3 | 19.1 Million USD | -6.83% |
| 1994 FY | 20.5 Million USD | -39.53% |
| 1994 Q4 | 16 Million USD | -16.23% |
| 1994 Q1 | 22.7 Million USD | 5.09% |
| 1993 Q1 | 40 Million USD | 42.86% |
| 1993 Q4 | 21.6 Million USD | -20.3% |
| 1993 FY | 33.9 Million USD | -13.74% |
| 1993 Q3 | 27.1 Million USD | -20.06% |
| 1993 Q2 | 33.9 Million USD | -15.25% |
| 1992 Q3 | 33.6 Million USD | -14.5% |
| 1992 FY | 39.3 Million USD | -27.49% |
| 1992 Q4 | 28 Million USD | -16.67% |
| 1992 Q2 | 39.3 Million USD | -14.19% |
| 1992 Q1 | 45.8 Million USD | -6.15% |
| 1991 FY | 54.2 Million USD | 86.25% |
| 1991 Q4 | 48.8 Million USD | -4.69% |
| 1991 Q1 | 20.4 Million USD | -12.82% |
| 1991 Q3 | 51.2 Million USD | -5.54% |
| 1991 Q2 | 54.2 Million USD | 165.69% |
| 1990 Q4 | 23.4 Million USD | -10.69% |
| 1990 Q2 | 29.1 Million USD | 0.0% |
| 1990 Q3 | 26.2 Million USD | -9.97% |
| 1990 FY | 29.1 Million USD | 117.16% |
| 1989 Q2 | 13.4 Million USD | 0.0% |
| 1989 FY | 13.4 Million USD | 19.64% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -2064921.645% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -2336.026% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -351.98% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -8539.788% |
| Rebus Holdings, Inc. | 5000.00 USD | -953940.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 63.366% |
| Qrons Inc. | 420.00 USD | -11357519.048% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -6089.888% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -70.706% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -9826.398% |
| Skye Bioscience, Inc. | 11.94 Million USD | -299.5% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -22.795% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -560.714% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -62374.788% |
| SQZ Biotechnologies Company | 107.18 Million USD | 55.496% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -3231.071% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -65818.607% |
| Mesoblast Limited | 667.9 Million USD | 92.858% |
| Marizyme, Inc. | 22.01 Million USD | -116.679% |
| Genus plc | 1.02 Billion USD | 95.364% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -3411.753% |
| Pharming Group N.V. | 462.85 Million USD | 89.694% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -1339.838% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -9458.772% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -7507.974% |
| ContraFect Corporation | 20.67 Million USD | -130.678% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -12119.814% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -12381.651% |
| IMV Inc. | 31.33 Million USD | -52.238% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -1050.549% |
| MultiCell Technologies, Inc. | 126.22 USD | -37792642.83% |
| ONE Bio Corp. | 70.08 Million USD | 31.937% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -4976.36% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 62.881% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -10949.445% |
| Q BioMed Inc. | 3.51 Million USD | -1256.899% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -35.598% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -18157.252% |
| Biomind Labs Inc. | 73.81 Thousand USD | -64520.22% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 89.312% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -3192.42% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -58.927% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1636.933% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -6838.614% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1732.44% |
| GB Sciences, Inc. | 103.44 Thousand USD | -46014.731% |
| Alpha Cognition Inc. | 2.45 Million USD | -1845.297% |
| HST Global, Inc. | 1526.00 USD | -3125850.197% |
| CSL Limited | 38.02 Billion USD | 99.875% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -4728.299% |
| Halberd Corporation | 10.13 Thousand USD | -470751.841% |
| Enzolytics Inc. | 361.7 Million USD | 86.812% |
| Agentix Corp. | 261.39 Thousand USD | -18149.22% |
| Resverlogix Corp. | 8.11 Million USD | -487.825% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -2440.205% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 98.95% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -7357.446% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -209293.793% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -433.034% |
| AVAX Technologies, Inc. | 7.37 Million USD | -546.618% |
| Zenith Capital Corp. | 7410.00 USD | -643651.687% |
| Genscript Biotech Corporation | 3.38 Billion USD | 98.591% |
| Ember Therapeutics, Inc. | 184.00 USD | -25924900.0% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -14723.216% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -18151.175% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -5040.518% |
| Kadimastem Ltd | 2.3 Million USD | -1970.327% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1476.881% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 9.486% |
| BioStem Technologies, Inc. | 14.56 Million USD | -227.617% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -83449.935% |
| LadRx Corporation | 2.3 Million USD | -1966.917% |
| Cell Source, Inc. | 195.17 Thousand USD | -24341.131% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -13389.736% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -13389.736% |
| NovAccess Global Inc. | 62.24 Thousand USD | -76532.181% |
| Affymax, Inc. | 7.44 Million USD | -540.897% |
| Itoco Inc. | 1.4 Million USD | -3307.11% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -49767.757% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -44901.887% |
| Mobile Lads Corp. | 52.00 USD | -91734515.385% |
| CytoDyn Inc. | 11.13 Million USD | -328.358% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -33264.575% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -266689.709% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -12274.991% |
| SYBLEU INC | 330.46 Thousand USD | -14334.681% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -11551.059% |
| International Stem Cell Corporation | 5.39 Million USD | -785.009% |
| Bioxytran, Inc. | 137.63 Thousand USD | -34557.58% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -217.975% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -187.725% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -60282.278% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -5416.742% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -534.588% |
| Neutra Corp. | 2851.00 USD | -1673067.31% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -47.201% |
| PureTech Health plc | 693.97 Million USD | 93.126% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -491.023% |
| IXICO plc | 15.84 Million USD | -201.075% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -475.972% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 53.833% |
| CSL Limited | 38.02 Billion USD | 99.875% |
| Cellectis S.A. | 333.99 Million USD | 85.718% |